Skip to main content
Erschienen in: Journal of Hematology & Oncology 1/2010

Open Access 01.12.2010 | Editorial

Sweet fruit from a poisonous kiss

verfasst von: Delong Liu

Erschienen in: Journal of Hematology & Oncology | Ausgabe 1/2010

Editorial

Acute promyelocytic leukemia (APL), once a rapidly fatal disease, has become most curable of all leukemias, thanks to the two Chinese wonder drugs, all-trans retinoid acid and arsenic trioxide (AT). PML-RXARα fusion protein is the hallmark and driving force of APL. In the April 9th issue of the journal, Science, Zhang et al. provided new and convincing evidence on how AT, an ancient poisonous medicine, plays the tricks on the oncoprotein, PML-RARα, and sheds lights on how a poisonous kiss leads to the sweet fruit [1].

A comprehensive approach and an epic story of science

Zhang et al. have indeed done a tremendous amount of work in this study. Several cell lines and transfectants were used and/or established, including HEK 293T, NB4, and HeLa cells, to name a few. Numerous mutants of PML as well as EGFP-fusion proteins were generated to pinpoint the kissing spot of AT. To be even more convincing, two additional organic arsenicals, PAPAO, and ReAsH, were also employed. With collaborations from the leading institutions of biotechnology and physics in China, MALDI-TOF mass spectrometry, EXAFS, XANES spectroscopy, and circular dichroism were orchestrated marvelously into the study. As the study evolves, it reads like an epic story of science.

Solid evidences-with no stones left unturned

The scientific team has provided strong and convincing evidence step by step and proved to the world that AT poisons the PML-RARa protein by kissing the cysteine residues in the zinc fingers within the RBCC domain of PML. They first demonstrated that AT binds to PML-, not the RARα - portion of the fusion oncoprotein. Using EGFP-fusion mutants of PML protein, they showed colocalization of arsenicals with various PML mutants, and pinpointed that AT binds to the RING domain of PML. With the help of NMR and a variety of technologies of physics, arsenic-sulfur bonds were proven to form through the conserved cysteine residues, and the number of arsenic atoms bound to the PML peptides were also defined. The biological consequences of arsenic binding to PML, the enhanced interaction of PML with UBC9 leading to increased degradation of PML-RARα, were further explored both in vitro and in vivo. In the end, a working model was proposed to explain how the poisonous kiss controls the fate of PML-RARα and leads to the sweet cure of APL.

Masterful collaborations between leading Chinese institutions and international laboratories

As soon as you read the study, it is obvious that the success of this remarkable work proves again the importance of collaborations between major leading institutions in China as well as with international laboratories. With the vast experience and knowledge from decades long of scientific endeavors in the world-renowned laboratories of Drs. Zhu Chen and Sai-Juan Chen, the collaborations between leading Chinese institutions and international laboratories were skillfully mastered to utilize the necessary tools and technology and generate the convincing and authoritative scientific data. This sets up a historical example in China for collaborations among leading laboratories and institutions to embark on scientific frontiers and achieve international leadership quickly and effectively.

Acknowledgements

I am indebted to Drs. Zihai Li and Ruirong Yuan for their critical review of the manuscript.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Literatur
1.
Zurück zum Zitat Zhang X-W, Yan Xiao-Jing, Zhou Zi-Ren, Yang Fei-Fei, Wu Zi-Yu, Sun Hong-Bin, Liang Wen-Xue, Song Ai-Xin, Lallemand-Breitenbach Valérie, Jeanne Marion, Zhang Qun-Ye, Yang Huai-Yu, Huang Qiu-Hua, Zhou Guang-Biao, Tong Jian-Hua, Zhang Yan, Wu Ji-Hui, Hu Hong-Yu, de Thé Hugues, Chen Sai-Juan, Chen Zhu: Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML. Science. 2010, 328: 240-243. 10.1126/science.1183424.CrossRefPubMed Zhang X-W, Yan Xiao-Jing, Zhou Zi-Ren, Yang Fei-Fei, Wu Zi-Yu, Sun Hong-Bin, Liang Wen-Xue, Song Ai-Xin, Lallemand-Breitenbach Valérie, Jeanne Marion, Zhang Qun-Ye, Yang Huai-Yu, Huang Qiu-Hua, Zhou Guang-Biao, Tong Jian-Hua, Zhang Yan, Wu Ji-Hui, Hu Hong-Yu, de Thé Hugues, Chen Sai-Juan, Chen Zhu: Arsenic trioxide controls the fate of the PML-RARα oncoprotein by directly binding PML. Science. 2010, 328: 240-243. 10.1126/science.1183424.CrossRefPubMed
Metadaten
Titel
Sweet fruit from a poisonous kiss
verfasst von
Delong Liu
Publikationsdatum
01.12.2010
Verlag
BioMed Central
Erschienen in
Journal of Hematology & Oncology / Ausgabe 1/2010
Elektronische ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-3-19

Weitere Artikel der Ausgabe 1/2010

Journal of Hematology & Oncology 1/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.